Residual microvascular risk in diabetes: Unmet needs and future directions

Nature Reviews Endocrinology

Volumn 6, Issue 1, 2010, Pages 19-25

  Fioretto, Paola ^a   Dodson, Paul M ^b   Ziegler, Dan ^c   Rosenson, Robert S ^d  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ATORVASTATIN; BEZAFIBRATE; CLOFIBRATE; CREATININE; ETOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ALBUMIN BLOOD LEVEL; ALBUMINURIA; AUTONOMIC NEUROPATHY; BLOOD VISCOSITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE COURSE; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HEALTH CARE NEED; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE; LIPID STORAGE; MICROALBUMINURIA; MICROANGIOGRAPHY; MICROCIRCULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETINA MACULA EDEMA; RETINA MACULOPATHY; REVIEW; RISK REDUCTION; SYNDROME X; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL ACUITY;

ANIMALS; BLOOD GLUCOSE; CAPILLARIES; CORONARY ANGIOGRAPHY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS;

EID: 73949146012     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.213     Document Type: Review

References (64)

1. International Diabetes Federation (IDF) Diabetes atlas (e-Atlas) [online] .ast;http://www.eatlas.idf.org/ index2983.html (2008).
2. Centers for Disease Control and Prevention (CDC) Diabetes data and trends [online] .ast;http://www.cdc.gov/diabetes/statistics/prev/ national/figpersons. htm (2008).
3. Jörneskog, G. et al. Early microvascular dysfunction in healthy normal-weight males with heredity for type 2 diabetes. Diabetes Care 28, 1495-1497 (2005).
4. Centers for Disease Control and Prevention (CDC) National Diabetes Fact Sheet [online] .ast;http://www.cdc.gov/diabetes/pubs/pdf/ ndfs-2007.pdf (2007).
5. Ziegler, D. et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 31, 464-469 (2008).
6. Fang, Z. Y. , Prins, J. B. & Marwick, T. H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 25, 543-567 (2004).
7. ADVANCE Collaborative Group et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572 (2008).
8. Patel, A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829-840 (2007).
9. The Action to Control Cardiovascular Risk in Diabetes Study Group et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
10. Gaede, P. , Vedel, P. , Parving, H. H. & Pedersen, O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353, 617-622 (1999).
11. Gaede, P. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348, 383-393 (2003). (Pubitemid 36159355)
12. Gaede, P. , Lund-Andersen, H., Parving, H. H. & Pedersen, O. Effect of a multifactorial intervention in mortality in type 2 diabetes. N. Engl. J. Med. 358, 580-591 (2008).
13. Shilo, S., Roy., S., Khanna, S. & Sen, C. K. Evidence for the involvement of miRNA in redox regulated angiogenic response of human microvascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28, 471-477 (2008).
14. Orchard, T. J. et al. Factors associated with avoidance of severe complications after 25 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 13, 741-747 (1990).
15. Miljanovic, B., Glynn, R. J., Nathan, D. M., Manson, J. E. & Schaumberg, D. A. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 53, 2883-2892 (2004).
16. Davis, M. D. et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss. Early Treatment Diabetic Retinopathy Study Report # 18. Invest. Ophthalmol. Vis. Sci. 39, 233-252 (1998).
17. Hadjadj, S. et al. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab. 30, 43-51 (2004).
18. Lyons, T. J. et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest. Ophthalmol. Vis. Sci. 45, 910-918 (2004).
19. Chew, E. Y. et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch. Ophthalmol. 114, 1079-1084 (1996).
20. Dodson, P. M. Medical treatment for diabetic retinopathy: do the FIELD microvascular study results support a role for lipid lowering? Practical Diabetes International 25, 76-79 (2008).
21. Harrold, B. P. , Marmion, V. J. & Gough, K. R. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 18, 285-291 (1969).
22. Freybarger, H., Schifferdecker, E. & Schatz, H. Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipaemic agent [German]. Med. Klin. (Munich) 89, 594-597 (1994).
23. Keech, A. C. et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370, 1687-1697 (2007).
24. Keech, A. et al. Effect of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
25. Kim, J. et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp. Eye Res. 84, 886-893 (2007).
26. Goetze, S. et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem. Biophys. Res. Comm. 293, 1431-1437 (2002).
27. Rosenson, R. S., Wolff, D. A., Huskin, A. L., Helenowski, I. B. & Rademaker, A. W. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30, 1945-1951 (2007).
28. Tsimihodimos, V. , Liberopoulos, E. & Elisaf, M. Pleiotropic effects of fenofibrate. Curr. Pharm. Des. 15, 517-528 (2009).
29. Ansquer, J. C., Foucher, C., Aubonnet, P. & Le Malicot, K. Fibrates and microvascular complications in diabetes--insight from the FIELD study. Curr. Pharm. Des. 15, 537-552 (2009).
30. Retnakaran, R. et al. Risk factors for renal dysfunction in type 2 diabetes. UK Prospective Diabetes Study 74. Diabetes 55, 1832-1839 (2006).
31. Molitch, M. E., Rupp, D. & Carnethon, M. Higher levels of HDL cholesterol are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes. Diabetes Care 29, 78-82 (2006).
32. Sandhu, S., Wiebe, N., Fried, L. F. & Tonelli, M. Statins for improving renal outcomes: a meta-analysis. J. Am. Soc. Nephrol. 17, 2006-2016 (2006).
33. Douglas, K., O'Malley, P. G. & Jackson, J. L. Meta-analysis: the effect of statins on albuminuria. Ann. Intern. Med. 145, 117-124 (2006).
34. Atthobari, J. et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol. Dial. Transplant. 21, 3106-3114 (2006).
35. Rahman, M. et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am. J. Kidney Dis. 52, 412-424 (2008).
36. Vidt, D. G. Statins and proteinuria. Curr. Atheroscler. Rep. 7, 351-357 (2005).
37. Law, M. & Rudnicka, A. R. Statin safety: a systematic review. Am. J. Cardiol. 97 (Suppl. 1), 52C-60C (2006).
38. Ozsoy, R. C., van Leuven, S. I., Kastelein, J. J., Arisz, L. & Koopman, M. G. The dyslipidemia of chronic renal disease: effects of statin therapy. Curr. Opin. Lipidol. 17, 659-666 (2006).
39. Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248 (2005). (Pubitemid 41058323)
40. Smulders, Y. M. et al. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur. J. Clin. Invest. 27, 997-1002 (1999).
41. Nagai, T., Tomizawa, T., Nakajima, K. & Mori, M. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J. Atheroscler. Thromb. 7, 91-96 (2000).
42. Ansquer, J. C. et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. 45, 485-493 (2005).
43. Hottleart, C., El Esper, N., Rose, F. , Achard, J. M. & Fournier, A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 92, 536-541 (2002).
44. Rossing, P. et al. Fish oil in diabetic nephropathy. Diabetes Care 19, 1214-1219 (1996).
45. Tesfaye, S. et al. Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 352, 341-350 (2005).
46. Kempler, P. et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet. Med. 19, 900-909 (2002).
47. Davis, T. M., Yeap, B. B., Davis, W. A. & Bruce, D. G. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 51, 562-566 (2008).
48. Welzig, C. M. et al. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness. Circulation 108, 2743-2746 (2003).
49. Rajamani, K. et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373, 1780-1788 (2009).
50. Corrao, G. et al. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases. J. Epidemiol. Community Health 58, 1047-1051 (2004).
51. Okuda, Y. et al. Long-term effects of eicosapenaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus. J. Diabetes Complications 10, 280-287 (1996).
52. Lee, B. K. et al. Microcirculatory dysfunction in cardiac syndrome X: role of abnormal blood rheology. Microcirculation 15, 451-459 (2003).
53. Kayikcioglu, M. et al. Benefits of statin treatment in cardiac syndrome-X1. Eur. Heart J. 24, 1999-2005 (2003).
54. Bonetti, P. O. et al. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent on lipid lowering. J. Am. Coll. Cardiol. 40, 546-554 (2002).
55. Rim, S. J. et al. Decrease in coronary blood flow reserve during hyperlipidemia is secondary to an increase in blood viscosity. Circulation 104, 2704-2709 (2001).
56. Labios, M. et al. Effect of a modified fibrate (Biniwas Retard) on hemorheological alterations in hyperlipemic patients. Clin. Hemorheol. Microcirc. 21, 79-85 (1999).
57. Frost, R. J., Otto, C., Geiss, H. C., Schwandt, P. & Parhofer, K. G. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol. 87, 44-48 (2001).
58. Rosenson, R. S. & Helenowski, I. B. Fenofibrate abrogates postprandial blood viscosity among hypertriglyceridemia subjects with the metabolic syndrome. Diabetes Met. Syndrome Clin. Res. Rev. 3, 17-23 (2009).
59. Zheng, F. & Guan, Y. Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy? Kidney Int. 72, 1301-1303 (2007).
60. Nakamura, T. et al. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 50, 1193-1196 (2001).
61. Ohga, S. et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am. J. Physiol. Renal Physiol. 292, F1141-F1150 (2007).
62. Fong, D. S. & Contreras, R. Glitazone use associated with diabetic macular edema. Am. J. Ophthalmol. 147, 583e1-586e1 (2009).
63. Martin, P. M. et al. Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium. Mol. Vis. 15, 362-372 (2009).
64. R3i studies. Microvascular residual risk epidemiological study. [online] .ast;http:// www.r3i.org/v1/studies.asp (2009).